000 02359nam  2200373zi 4500
0019.875989
003CaOODSP
00520240220151437
006m     o  d f      
007cr |||||||||||
008190708t20022002abc    #o    f000 0 eng d
040 |aCaOODSP|beng|erda|cCaOODSP
041 |aeng|bfre
043 |an-cn---
0861 |aD68-3/170-2002E-PDF
24500|aChemical weapon agent studies in domestic swine : |bpart 5 : comparative bioavailability of different HI-6 salt forms in the domestic pig / |cprepared by: Kinchyle Enterprises Inc.
24610|aComparative bioavailability of different HI-6 salt forms in the domestic pig
264 1|aMedicine Hat, Alberta, Canada : |bDefence Research and Development Canada = Recherche et développement pour la défense Canada, |c2002.
264 4|c©2002
300 |a1 online resource (ii, 37 pages, 2 unnumbered pages).
336 |atext|btxt|2rdacontent
337 |acomputer|bc|2rdamedia
338 |aonline resource|bcr|2rdacarrier
4901 |aContract report ; |vDRDC Suffield CR 2002-C170
500 |a"September 2002."
500 |a"PWGSC Contract Number: W7702-99-R785."
5203 |a"A well-developed anesthetized domestic swine model has been utilized to study the following effect of chemical weapons (CW): 01 - Comparative bioavailability of different HI-6 salt forms in the domestic pig. The bioavailability of the dihydrochloride salt of HI-6a (currently utilized) was compared to that of the dimethanesulfonate salt (HI-6b). The latter is more water-soluble at low temperatures. The salts appear similarly clinically, biochemically or hematologically in the "equivalent" doses administered (HI-6 dihychloride = 500 mg, HI-6 dimethanesulfonate = 633 mg.) A notable exception might be the observation that the combination of pyridostigmine (PYR)/HI-6b increases airway resistance. Timed plasma and urine samples were collected for HPLC analysis"--Abstract, page i.
546 |aIncludes abstract in French.
69207|2gccst|aHogs
69207|2gccst|aChemical weapons
69207|2gccst|aBioassay
7101 |aDefence R&D Canada - Suffield.
830#0|aContract report (Defence R&D Canada)|vDRDC Suffield CR 2002-C170.|w(CaOODSP)9.802312
85640|qPDF|s6.37 MB|uhttps://publications.gc.ca/collections/collection_2019/rddc-drdc/D68-3-170-2002-eng.pdf